Epilepsy medicines and pregnancy

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated safety guidance following a comprehensive review of epilepsy medications and their risks during pregnancy. The review identified significant safety concerns, particularly with valproate (Epilim, Depakote), which is associated with a 10% risk of physical birth abnormalities and a 30-40% risk of lifelong developmental disabilities. Other medications, including Carbamazepine, Phenobarbital, Phenytoin, and Topiramate, were also found to increase the risk of physical defects, while Lamotrigine and Levetiracetam were identified as safer alternatives that do not increase these risks compared to the general population. Under the regulatory framework of the valproate pregnancy prevention programme ('prevent'), the MHRA has implemented stricter usage controls for women of childbearing potential. Required actions for patients include scheduling pre-conception counseling with a specialist before becoming pregnant and continuing current treatments until a medical professional agrees on a safe transition plan. Patients are advised to use highly effective contraception during treatment changes and are encouraged to report any side effects through the MHRA Yellow Card scheme.